Our previous in vitro study indicated that idarubicin-ZHER2 affibody conjugate could be successfully used for specific ablation of HER2-overexpressed HN-5 cells originated from head and neck squamous cell carcinoma (HNSCC) (23). The gene discussed is ERBB2; the disease is head and neck squamous cell carcinoma.